Causeway Capital Management opened a $24.4M position in NOVO NORDISK A/S
Sarah Ketterer of Causeway Capital Management has filed a new position in NOVO NORDISK A/S, investing $24.4 million as of the 2025-08-13 filing date, reflecting a strategic move in the healthcare sector.
New Investment by Causeway Capital Management
Causeway Capital Management, led by Sarah Ketterer, has recently established a new position in NOVO NORDISK A/S. This investment amounts to $24.4 million, as reported on the filing date of 2025-08-13, with a total of 353,884 shares acquired.
Significance and Portfolio Impact
The new position represents 0.39% of Causeway Capital Management's portfolio as of the period ending on 2025-06-30. This move underscores the firm's strategic focus on the healthcare sector, known for its stability and growth potential.
Strategic Considerations
NOVO NORDISK A/S, a leading global healthcare company, specializes in diabetes treatments and innovative medicines. This investment highlights Causeway Capital Management's confidence in NOVO NORDISK's ability to maintain its leadership in the healthcare industry.